Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJ787
- Development stage
- Phase 2
- Lead developer
- 成都华健未来科技
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HJ787 is a novel, topical small molecule androgen receptor (AR) antagonist developed by Chengdu Huajian Future Technology for the treatment of acne vulgaris. The drug is designed to specifically target and inhibit the androgen receptor within the skin's sebaceous glands, thereby reducing sebum production, which is a key driver in the pathogenesis of acne. By utilizing a topical formulation, HJ787 aims to provide localized therapeutic effects while minimizing systemic exposure and the potential for systemic anti-androgenic side effects. It is currently being evaluated in clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with moderate-to-severe acne.
- Other names
- HJ787 OintmentHJ-787 OintmentHJ 787 Ointment
Beyond the preview
Go deeper on HJ787.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJ787.